Tibsovo 250 mg Tablet Supplier USA | Pharmaceutical Exporter India

Tibsovo 250 mg Tablet: Precision IDH1 Targeted Therapy for AML, MDS, and Cholangiocarcinoma

Are you looking for a trusted Tibsovo 250 mg Tablet exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global bulk supplier and distributor of breakthrough precision medicines. We maintain a high-authority supply chain serving the USA, UK, Australia, and South Africa, ensuring that next-generation targeted therapies reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Tibsovo 250 mg?

Tibsovo 250 mg (Ivosidenib) is a first-in-class, oral targeted therapy designed to treat cancers driven by a specific genetic mutation. It is a potent, selective inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) enzyme.

Manufactured by Servier Pharmaceuticals, Tibsovo represents a major shift in oncology from broad-spectrum chemotherapy to mutation-specific precision medicine. For international B2B procurement, Tibsovo 250 mg offers a clinically superior solution for patients whose cancers have been molecularly profiled to harbor an IDH1 mutation.

Primary Therapeutic Indications

Tibsovo 250 mg is clinically indicated for the management of the following:

1. Acute Myeloid Leukemia (AML): * For newly diagnosed AML in adults $\ge$ 75 years or those with comorbidities that preclude intensive induction chemotherapy.

   • For adults with relapsed or refractory AML.

2. Myelodysplastic Syndromes (MDS): For adult patients with relapsed or refractory MDS with a susceptible IDH1 mutation.

3. Cholangiocarcinoma (Bile Duct Cancer): For adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation.

Mechanism of Action: How Tibsovo Works

Tibsovo targets the molecular root of cancer growth by normalizing cell differentiation:

• Blocking the Mutant Enzyme: In certain cancers, the IDH1 enzyme mutates, leading to the overproduction of an oncometabolite called 2-HG (2-hydroxyglutarate).

• Preventing 2-HG Accumulation: High levels of 2-HG block normal cell differentiation, causing immature "blast" cells to multiply. Tibsovo binds to the mutant IDH1 to stop 2-HG production.

• Restoring Normal Function: By lowering 2-HG levels, Tibsovo allows immature leukemia or cancer cells to mature into normal, functioning cells, effectively halting the progression of the disease.

Administration and Safety Guidelines

• Standard Dosage: The typical dose is 500 mg (two 250 mg tablets) taken orally once daily with or without food. Avoid high-fat meals as they can significantly increase absorption.

• Monitoring: Regular blood counts and EKG monitoring are essential during treatment.

• Key Precautions:

  • Differentiation Syndrome: A serious condition in AML/MDS patients characterized by fever and respiratory distress; requires immediate medical attention.

  • QTc Prolongation: Monitor heart rhythm, especially in patients with pre-existing heart conditions.

  • Guillain-Barré Syndrome: Monitor for new onset of weakness or tingling in extremities.

Why Source Tibsovo from Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine international brands, ensuring 100% product authenticity and competitive bulk pricing.

• Logistics Mastery: Expert handling of sensitive specialty medications with a focus on timely delivery to the USA, UK, Australia, and South Africa.

• Regulatory Compliance: We adhere to strict GMP standards and provide all necessary documentation, including Certificates of Analysis (COA).

• B2B Supply Continuity: We specialize in large-scale procurement for government tenders, private hospitals, and regional medical distributors.